Purple Biotech Ltd. announced it is advancing NT219, a novel drug aimed at overcoming tumor resistance to therapy, into a Phase 2 clinical trial for patients with recurrent/metastatic squamous cell ...
April 21 (Reuters) - Merck and Eisai's experimental combination treatments for a type of kidney cancer failed to meet the ...
In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to why lupus symptoms and severity present differently in individuals with the autoimmune condition, which ...
In a new study, researchers from Johns Hopkins Medicine say they have uncovered insights as to why lupus symptoms and severity present differently in individuals with the autoimmune condition, which ...
Stocktwits on MSN
CYDY stock falls despite positive cancer study data – retail says CytoDyn is 'here to stay'
The study evaluated Leronlimab, an investigational antibody, in combination with standard therapies TAS-102 and Bevacizumab, a targeted therapy that blocks tumor growth. ・The study showed positive ...
Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven ...
A new study led by researchers at National Jewish Health has revealed that, while a wide range of viruses can cause lower respiratory tract illnesses (LRIs) in infants, certain viruses and viral ...
A randomized phase 2 study of combination atezolizumab and varlilumab (CDX-1127) with or without addition of cobimetinib in previously treated unresectable biliary tract cancer. This is an ASCO ...
AstraZeneca AZN has announced positive results from the phase III CAPItello-281 study, which evaluated a combination regimen involving its ATK inhibitor Truqap (capivasertib) in certain patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results